Review examines metabolic and epigenetic networks in vascular calcification and multi-target treatment strategies
Background: Osteogenic transition of vascular smooth muscle cells
A review in the European Journal of Pharmacology summarizes metabolic, mitochondrial, and epigenetic mechanisms driving vascular calcification, along with directions for developing multi-target treatments. Focusing on the osteogenic transition of vascular smooth muscle cells (VSMCs), the paper surveys related research and examines how intracellular changes and intercellular signals form a network that sustains the pathology.
Vascular calcification is a multifactorial disease associated with aging, chronic kidney disease, and diabetes. The abstract describes it as a major cause of cardiovascular death. At the center of the process is the shift of VSMCs toward osteogenic properties. The authors ask which mechanisms jointly drive this transition and how their connections might inform treatment development.
Key findings: Links between intracellular changes and intercellular signals
The review focuses on three mechanistic axes. The first is metabolic reprogramming centered on polyamine metabolism and metabolite signaling. The second is the interaction between mitochondrial dysfunction and ferroptosis. The third is epigenetic regulation that stabilizes the osteogenic phenotype. This category includes histone modifications, DNA methylation, and non-coding RNAs.
These mechanisms are discussed as interconnected processes. However, the available abstract does not report the contribution or effect size of individual pathways, or the experimental conditions. It is therefore difficult to judge how strongly a particular metabolic change induces osteogenesis or whether the phenotypic change is permanent.
Communication between cells is another major focus. The abstract states that extracellular vesicles and bidirectional signaling between endothelial cells and VSMCs amplify pathological intracellular changes, forming a self-sustaining pathological network. This perspective considers interactions with neighboring cells as well as changes within the cells themselves. The provided material does not identify the specific substances carried by the vesicles or quantify the effects of signal transmission.
Significance and outlook: Treatment candidates and validation challenges
Within this mechanistic framework, the review presents targeted protein degradation (TPD), modulation of biased signaling in G protein-coupled receptors (GPCRs) using molecular glues, ferroptosis inhibition, drug repurposing, and gene editing as emerging therapeutic approaches. The review considers multiple mechanisms and intervention strategies together, but should not be interpreted as a study demonstrating the therapeutic efficacy of a particular combination. The abstract reports no findings showing that combining these approaches reversed calcification or permanently eliminated a specific target.
The review mentions SNF472 and ataciguat as clinical development examples. Its abstract describes both as drug candidates undergoing clinical trials at the time, but does not specify trial phase, participant characteristics, comparator groups, endpoints, or effect sizes. The available evidence is insufficient to conclude that either had reached the final stage of validation or that efficacy in patients had been established.
This review provides a framework for considering the interconnected mechanisms of vascular calcification and treatment candidates together. Assessing the effectiveness of actual multi-target interventions and their clinical applicability will require examining the specific evidence from individual studies and clinical trials. The scope and bibliographic information of the paper can be checked in the provided Europe PMC abstract.
Cardiovascular & Epigenomic Engineering Core, Published May 2026.
Summary: Resolving the multifactorial therapeutic bottlenecks governing vascular calcification, this critical review systematizes the programmatic pathways driving the osteogenic conversion of vascular smooth muscle cells (VSMCs). Beyond single-target metabolic options, the framework captures the dynamic intersections link polyamine metabolic reprogramming with the synergistic loops of mitochondrial dysfunction and ferroptosis cascades. The platform highlights how these cell-autonomous shifts are heritably sustained via the epigenetic stabilization of histone modifications, DNA methylation vectors, and non-coding RNA networks, all amplified by long-range extracellular vesicle translocation. To arrest this pathological web, several emerging multi-targeted paradigms are evaluated—specifically targeted protein degradation (TPD), molecular glues for biased GPCR signaling, and site-specific gene editing. Interlinking these with clinical-stage investigational assets including SNF472 and ataciguat delivers a scalable, low-noise computational baseline for high-throughput cardiovascular translational screening and prospective biomarker stratification.
For researchers evaluating treatment candidates for vascular calcification, this review can serve as a starting point for organizing the evidence. For example, it may inform study plans that assess metabolic changes, mitochondrial function, ferroptosis, epigenetic regulation, and intercellular signaling together when evaluating candidate targets. This is a possible application of the multi-target development direction proposed by the review, not evidence that a particular combination strategy is superior. Further data on experimental conditions, efficacy, and safety for each approach are needed to translate candidates into actual development. The abstract’s mention of SNF472 and ataciguat alone is also insufficient to guide treatment choices for patients or determine their current development status.